Clinical Trial Detail

NCT ID NCT01028222
Title A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Nilotinib

Age Groups: adult

Additional content available in CKB BOOST